Archives of Neuroscience

Published by: Kowsar
Corrected Proof scheduled for 6 (1)

The Role of Susceptibility-Weighted Imaging and Dedicated MRI Protocols in the Diagnostic Evaluation of Patients with Drug-Resistant Epilepsy

Sakineh Ranji-Burachaloo 1 , Payam Sarraf 1 , ** , Elham Rahimian 2 , Shirin Shakiba 1 , Nina Javadian 1 , Parastoo Faraji 3 and Abbas Tafakhori 1 , *
Authors Information
1 Department of Neurology, Imam Khomeini Hospital, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Neuroradiology, Haghighat Medical Imaging Center, Tehran, Iran
3 Imam Khomeini Hospital, Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
Corresponding Authors:
Article information
  • Archives of Neuroscience: February 2019, 6 (Special Issue); e68741
  • Published Online: November 11, 2018
  • Article Type: Research Article
  • Received: March 17, 2018
  • Accepted: October 10, 2018
  • DOI: 10.5812/ans.68741

To Cite: Ranji-Burachaloo S, Sarraf P, Rahimian E, Shakiba S, Javadian N, et al. The Role of Susceptibility-Weighted Imaging and Dedicated MRI Protocols in the Diagnostic Evaluation of Patients with Drug-Resistant Epilepsy, Arch Neurosci. 2019 ; 6(Special Issue):e68741. doi: 10.5812/ans.68741.

Copyright © 2018, Archives of Neuroscience. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Goodarzi P, Aghayan HR, Soleimani M, Norouzi-Javidan A, Mohamadi-Jahani F, Jahangiri S, et al. Stem cell therapy for treatment of epilepsy. Acta Med Iran. 2014;52(9):651-5. [PubMed: 25325201].
  • 2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9. doi: 10.1056/NEJM200002033420503. [PubMed: 10660394].
  • 3. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: Response to sequential treatment schedules. Eur J Neurol. 2006;13(3):277-82. doi: 10.1111/j.1468-1331.2006.01215.x. [PubMed: 16618346].
  • 4. Sander JW. Some aspects of prognosis in the epilepsies: A review. Epilepsia. 1993;34(6):1007-16. [PubMed: 8243349].
  • 5. Kwan P, Brodie MJ. Refractory epilepsy: A progressive, intractable but preventable condition? Seizure. 2002;11(2):77-84. doi: 10.1053/seiz.2002.0593. [PubMed: 11945093].
  • 6. Perucca P, Hesdorffer DC, Gilliam FG. Response to first antiepileptic drug trial predicts health outcome in epilepsy. Epilepsia. 2011;52(12):2209-15. doi: 10.1111/j.1528-1167.2011.03283.x. [PubMed: 21973181].
  • 7. Shackleton DP, Westendorp RG, Kasteleijn-Nolst Trenite DG, de Craen AJ, Vandenbroucke JP. Survival of patients with epilepsy: An estimate of the mortality risk. Epilepsia. 2002;43(4):445-50. [PubMed: 11952777].
  • 8. Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol. 2001;58(10):1543-6. [PubMed: 11594910].
  • 9. Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52(12):2181-91. doi: 10.1111/j.1528-1167.2011.03325.x. [PubMed: 22136077].
  • 10. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: A prospective study. Neurology. 2001;56(11):1445-52. [PubMed: 11402099].
  • 11. Nikodijevic D, Baneva-Dolnenec N, Petrovska-Cvetkovska D, Caparoska D. Refractory epilepsy-MRI, EEG and CT scan, a correlative clinical study. Open Access Maced J Med Sci. 2016;4(1):98-101. doi: 10.3889/oamjms.2016.029. [PubMed: 27275339]. [PubMed Central: PMC4884263].
  • 12. Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM. 1999;92(1):15-23. [PubMed: 10209668].
  • 13. Duncan JS. Imaging and epilepsy. Brain. 1997;120 ( Pt 2):339-77. [PubMed: 9117380].
  • 14. [No Authors Listed]. Recommendations for neuroimaging of patients with epilepsy. Commission on neuroimaging of the international league against epilepsy. Epilepsia. 1997;38(11):1255-6. [PubMed: 9579930].
  • 15. Saini J, Kesavadas C, Thomas B, Kapilamoorthy TR, Gupta AK, Radhakrishnan A, et al. Susceptibility weighted imaging in the diagnostic evaluation of patients with intractable epilepsy. Epilepsia. 2009;50(6):1462-73. doi: 10.1111/j.1528-1167.2008.01882.x. [PubMed: 19400870].
  • 16. Reichenbach JR, Haacke EM. High-resolution BOLD venographic imaging: A window into brain function. NMR Biomed. 2001;14(7-8):453-67. [PubMed: 11746938].
  • 17. Gasparotti R, Pinelli L, Liserre R. New MR sequences in daily practice: Susceptibility weighted imaging. A pictorial essay. Insights Imaging. 2011;2(3):335-47. doi: 10.1007/s13244-011-0086-3. [PubMed: 22347957]. [PubMed Central: PMC3259351].
  • 18. Mohammed W, Xunning H, Haibin S, Jingzhi M. Clinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: A review. Cancer Imaging. 2013;13:186-95. doi: 10.1102/1470-7330.2013.0020. [PubMed: 23618919]. [PubMed Central: PMC3636597].
  • 19. Lee BC, Vo KD, Kido DK, Mukherjee P, Reichenbach J, Lin W, et al. MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. AJNR Am J Neuroradiol. 1999;20(7):1239-42. [PubMed: 10472978].
  • 20. Deistung A, Mentzel HJ, Rauscher A, Witoszynskyj S, Kaiser WA, Reichenbach JR. Demonstration of paramagnetic and diamagnetic cerebral lesions by using susceptibility weighted phase imaging (SWI). Z Med Phys. 2006;16(4):261-7. [PubMed: 17216751].
  • 21. Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology. 2001;57(12):2259-64. [PubMed: 11756607].
  • 22. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: Post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012;11(4):331-40. doi: 10.1016/S1474-4422(12)70018-2. [PubMed: 22377180].
  • 23. French JA. Refractory epilepsy: Clinical overview. Epilepsia. 2007;48 Suppl 1:3-7. doi: 10.1111/j.1528-1167.2007.00992.x. [PubMed: 17316406].
  • 24. Liimatainen SP, Raitanen JA, Ylinen AM, Peltola MA, Peltola JT. The benefit of active drug trials is dependent on aetiology in refractory focal epilepsy. J Neurol Neurosurg Psychiatry. 2008;79(7):808-12. doi: 10.1136/jnnp.2007.132811. [PubMed: 17991701].
  • 25. Josephson CB, Leach JP, Duncan R, Roberts RC, Counsell CE, Al-Shahi Salman R, et al. Seizure risk from cavernous or arteriovenous malformations: Prospective population-based study. Neurology. 2011;76(18):1548-54. doi: 10.1212/WNL.0b013e3182190f37. [PubMed: 21536634]. [PubMed Central: PMC3100127].
  • 26. Pereira VM, Geibprasert S, Krings T, Aurboonyawat T, Ozanne A, Toulgoat F, et al. Pathomechanisms of symptomatic developmental venous anomalies. Stroke. 2008;39(12):3201-15. doi: 10.1161/STROKEAHA.108.521799. [PubMed: 18988912].
  • 27. Lee M, Kim MS. Image findings in brain developmental venous anomalies. J Cerebrovasc Endovasc Neurosurg. 2012;14(1):37-43. doi: 10.7461/jcen.2012.14.1.37. [PubMed: 23210028]. [PubMed Central: PMC3471249].
  • 28. Barnes SR, Haacke EM. Susceptibility-weighted imaging: Clinical angiographic applications. Magn Reson Imaging Clin N Am. 2009;17(1):47-61. doi: 10.1016/j.mric.2008.12.002. [PubMed: 19364599]. [PubMed Central: PMC2713115].
  • 29. Scheidegger O, Wiest R, Jann K, Konig T, Meyer K, Hauf M. Epileptogenic developmental venous anomaly: Insights from simultaneous EEG/fMRI. Clin EEG Neurosci. 2013;44(2):157-60. doi: 10.1177/1550059412464463. [PubMed: 23396079].
  • 30. Statler KD, Scheerlinck P, Pouliot W, Hamilton M, White HS, Dudek FE. A potential model of pediatric posttraumatic epilepsy. Epilepsy Res. 2009;86(2-3):221-3. doi: 10.1016/j.eplepsyres.2009.05.006. [PubMed: 19520549]. [PubMed Central: PMC2702176].
  • 31. Larkin M, Meyer RM, Szuflita NS, Severson MA, Levine ZT. Post-traumatic, drug-resistant epilepsy and review of seizure control outcomes from blinded, randomized controlled trials of brain stimulation treatments for drug-resistant epilepsy. Cureus. 2016;8(8). e744. doi: 10.7759/cureus.744. [PubMed: 27672534]. [PubMed Central: PMC5035081].
  • 32. Mannion RJ, Cross J, Bradley P, Coles JP, Chatfield D, Carpenter A, et al. Mechanism-based MRI classification of traumatic brainstem injury and its relationship to outcome. J Neurotrauma. 2007;24(1):128-35. doi: 10.1089/neu.2006.0127. [PubMed: 17263676].
  • 33. Tong KA, Ashwal S, Holshouser BA, Nickerson JP, Wall CJ, Shutter LA, et al. Diffuse axonal injury in children: Clinical correlation with hemorrhagic lesions. Ann Neurol. 2004;56(1):36-50. doi: 10.1002/ana.20123. [PubMed: 15236400].
  • 34. Helmstaedter C, Petzold I, Bien CG. The cognitive consequence of resecting nonlesional tissues in epilepsy surgery--results from MRI- and histopathology-negative patients with temporal lobe epilepsy. Epilepsia. 2011;52(8):1402-8. doi: 10.1111/j.1528-1167.2011.03157.x. [PubMed: 21740419].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments